

**HIGHLIGHTS**



**SINGAPORE**

3-8 / july / 2023

Con el patrocinio de:



Iniciativa científica de:






# PSORIASIS

## Highlights Singapore

**ROSA IZU BELLOSO**

**HOSPITAL UNIVERSITARIO BASURTO. BILBAO**

**[rosamaria.izubelloso@osakidetza.eus](mailto:rosamaria.izubelloso@osakidetza.eus)**



UCB ha financiado mi  
participación en este congreso

---

# HIGHLIGHTS

---



25th World Congress of Dermatology

# WEDV

---

# SINGAPORE

---

3-8 / july / 2023

Conflicto de interés

UCB ha financiado mi  
participación en este congreso

**HIGHLIGHTS**



25th World Congress of Dermatology  
**WEDV**

**SINGAPORE**

3-8 / july / 2023

# Reunión IPC



HIGHLIGHTS



SINGAPORE

3-8 / july / 2023



# Reunión IPC



< (SSM) International Psoriasis Council – IPC Psoriasis Management and Treatment...

Search...

☆☆☆☆

## A Patient-Inclusive Approach in the Treatment of Psoriasis: A Principal Without Borders

14:35 – 14:55

Speaker [Claudia de la Cruz](#) (Chile)

☆☆☆☆

## An International Perspective on Value-Based Healthcare

14:55 – 15:15

Speaker [Jo Lydie Lambert](#) (Belgium)

☆☆☆☆

## Genetic Differences Across the Globe

15:15 – 15:35

Speaker [Johann E. Gudjonsson](#) (USA)

☆☆☆☆

## Pitfalls in Diagnosis and Phenotypic Differences Related to Skin of Color

15:35 – 15:55

Speaker [Samiul Huq](#) (Bangladesh)

☆☆☆☆

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023

# Reunión IPC



< (SSM) International Psoriasis Council – IPC Psoriasis Management and Treatment...

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023

Search...

☆☆☆☆

A Patient-Inclusive Approach in the Treatment of Psoriasis: A F Borders

14:35 – 14:55

Speaker [Claudia de la Cruz](#) (Chile)

☆☆☆☆

An International Perspective on Value-Based Healthcare

14:55 – 15:15

Speaker [Jo Lydie Lambert](#) (Belgium)

☆☆☆☆

Genetic Differences Across the Globe

15:15 – 15:35

Speaker [Johann E. Gudjonsson](#) (USA)

☆☆☆☆

Pitfalls in Diagnosis and Phenotypic Differences Related to Sk

15:35 – 15:55

Speaker [Samiul Huq](#) (Bangladesh)

☆☆☆☆

Therapeutic Challenges Related to Skin of Color

16:10 – 16:30

Speaker [Mahira El Sayed](#) (Egypt)

☆☆☆☆

Comorbidities of Psoriasis Across the World

16:30 – 16:50

Speaker [Kathleen Gallant](#) (USA)

☆☆☆☆

Availability of Therapies Across the World: Data from the GPA

16:50 – 17:10

Speaker [Christopher Griffiths](#) (UK)

☆☆☆☆

Every Patient in the World has the Right to Optimal Treatment

17:10 – 17:30

Speaker [Hosea Wilfred Waweru](#) (Kenya)


☆☆☆☆

Closing remarks and adjourn

17:30 – 17:30

Speaker [Claudia de la Cruz](#) (Chile)

☆☆☆☆



[www.lapsoriasis.cl](http://www.lapsoriasis.cl)



More than 4000 online surveys obtained, with important information about our patients

Learned from our patients to better understand their unmet needs





## Our PsoPlus journey

- Since 2012 we started **structuring** (checklist !) our **health record** used during consultations, capturing data in a comprehensive and more complete way.
- We worked with **more personnel (+ nurse/admin)** around the patient and took **more time**.
- We put more emphasis on **education** of the patients.
- We installed a **communication** channel in **between consultations** with our patients.

We showed that patients are put more rapidly on more efficacious medication.

We showed that patients had to come back less often (better results).

<https://doi.org/10.3109/09546634.2015.1117566> DeCoster E et al. J Dermatol Treatment, 2016


<https://doi.org/10.1080/17843286.2020.1750747> Lambert J et al. Acta Clin Belg, 2021

## Value-Based Healthcare

$$\text{VALUE} = \frac{\text{PATIENT-RELEVANT OUTCOMES}}{\text{COSTS}}$$

## (1) Organize into Integrated Practice Units (IPUs)


- Organised over the full cycle of care around **a medical condition**, including patient education, engagement, monitoring, adherence, and follow-up
- Providers are part of a **common organizational unit**
- The team meets formally and informally on a regular basis (f.e. to **discuss outcomes and processes**)
- The team accepts **joint accountability** for outcomes and costs
- PsoPlus (Deprez/Hilhorst)



## (2) Measure Outcomes and Costs for Every Patient

### Patient-Relevant Outcomes

- Outcomes should be measured by **medical condition or primary care patient segment**. **Not** by procedure or intervention.
- Outcomes should reflect the **full cycle of care** for the condition.
- Outcomes are **always multi-dimensional** and should include the health results **most relevant to patients**.
- Measurement must include **initial conditions/risk factors** to allow for risk adjustment.
- Standardize** outcome measures to enable comparison and learning.



Example Psoriasis



# IPC- Genetic differences across the world

HIGHLIGHTS

SINGAPORE



3-8 / July / 2023


## Pathogenesis of Psoriasis

- Complex immunopathogenesis that can be linked to:

- Predisposing factors
- Disease initiation
- Disease maintenance

- Genetic predisposition with >86 genetic loci identified to date

- Interferon/antiviral signaling
- Epidermal differentiation
- Autoinflammatory responses
- IL-23/Th17 differentiation/IL-17 responses
- Antigen presentation
- Oxidative responses
- TNF/NFκB signaling
- T-cell development



Gudjonsson, Elder, Fitzpatrick 9<sup>th</sup> version

# IPC- Genetic differences across the world



## Phenotypic Racial differences in presentation

- **Plaque psoriasis is the most common type of psoriasis seen among all races.**
- **pustular psoriasis is more likely to be seen in Asian and Hispanic populations.**
- **Asian populations are also more likely to present with erythrodermic psoriasis and less likely to have inverse psoriasis.**
- **One study found that Asian and Hispanic populations are more likely to present with greater disease severity than Caucasian patients.**
- **East Asian patients often have smaller, less widespread plaques than Caucasian patients.**
- **Asian and Black patients are also more likely to present with scalp psoriasis.**

Medical News today: Medically reviewed by Raechele Cochran Gathers, MD — By Jenna Fletcher on August 31, 2022

# IPC- Phenotypic differences

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023



December 2022

Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color – Part I: Genetic, biologic, and structural differences in skin of color



Jessica B. Brown-Korsah, BS,<sup>a,b</sup> Shanice McKenzie, MD,<sup>c</sup> Deega Omar, BA, MPH,<sup>a,d</sup> Nicole C. Syder, BA,<sup>c</sup> Nada Elbuluk, MD, MSc,<sup>c</sup> and Susan C. Taylor, MD<sup>a</sup>

Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color



Shanice McKenzie, MD,<sup>a</sup> Jessica B. Brown-Korsah, BS,<sup>b,c</sup> Nicole C. Syder, BA,<sup>a</sup> Deega Omar, BA, MPH,<sup>d</sup> Susan C. Taylor, MD,<sup>c</sup> and Nada Elbuluk, MD, MSc<sup>d</sup>

# IPC- Phenotypic differences



## Genetics: HLA-Cw6



### • In Asian and Middle Easterner populations:

- Guttate psoriasis
- Early-onset psoriasis
- Psoriatic arthritis

Prevalence of HLA-Cw6:  
**higher** among Black  
populations

Prevalence of psoriasis:  
**Lower** among Black  
populations

other genes  
(besides HLA-Cw6)  
contribute to the  
development of psoriasis in  
Black individuals

Brown-Korsah JB, McKenzie S, Omar D, Syder NC, Elbuluk N, Taylor SC. Variations in genetics, biology, and phenotype of cutaneous disorders in Black populations: implications for clinical and structural differences in skin of color. *J Am Acad Dermatol.* 2022;87(6):1239-1258

## Genetics: HLA-Cw1



**Increased prevalence** in  
Asian & Middle Eastern  
populations

Increased severity in  
psoriasis

May be associated with  
generalized pustular  
psoriasis

## Scalp Treatment

- Treatment that includes **daily hair washing** with a prescription shampoo:
  - **Not a suitable option** for African-American female patients
  - May cause hair dryness, breakage, and interference with usual hair styling
  - Ultimately leading to **noncompliance & patient dissatisfaction**



Kaufman, B.P., Alexis, A.F. Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. *Am J Clin Dermatol* 19, 405–423 (2018)

## Genetics: Loricrin

### In Asians:

Downregulation of loricrin may impair barrier function of the stratum corneum in individuals with psoriasis



Review > J Dermatolog Treat. 2017 Mar;28(2):129-135. doi: 10.1080/09546634.2016.1183763.  
Epub 2016 May 19.

## Biologics

### Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region

Anwar Al Hammadi<sup>1</sup>, Afaf Al-Sheikh<sup>2</sup>, Alfred Ammoury<sup>3</sup>, Samer Ghosn<sup>4</sup>, Paolo Gisondi<sup>5</sup>,  
Issam Hamadah<sup>6</sup>, Abdul-Ghani Kibbi<sup>4</sup>, Khalid Shirazy<sup>7</sup>

- In the region, **currently only South Africa and Saudi Arabia have national guidelines**

This is a concern for several reasons:

#### 1. Psoriasis co-morbidities

- Such as metabolic syndrome, obesity, cardiovascular disease and PsA are particularly common in African and Middle Eastern patients
- May be under-recognized and under-treated




# IPC- Global psoriasis atlas

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023




## Global Psoriasis Atlas

*A collaboration between IFPA, ILDS, and IPC*

The aim of the GPA is to understand the number of people around the world who have psoriasis, and the care and treatment available to them.

- **Epidemiology of psoriasis**
- **Understand and characterize the economic impact**
- **Recognize the comorbid disease burden**
- **Improve early diagnosis**



- Chile
- Groenlandia (inuits)
- Tanzania
- Laos, Nepal...





## Phase III 2023-26

G P A

Global Psoriasis Atlas



### Epidemiology of Psoriasis (To Include Generalised Pustular Psoriasis)

Conduct new epidemiological studies



### Psoriasis Diagnosis

Validation studies commence with a focus on use of the tool to facilitate diagnosis of psoriasis in countries with diverse populations and in skin of colour



### Understand and Characterise the Economic Impact of Psoriasis

Conduct and publish new studies



### Recognise the Comorbid Disease Burden of Psoriasis

Examine clusters of multimorbidity in people with psoriasis, highlight potential for screening, management and treatment to mitigate or prevent effects of disease




### Global Collaborations

Field Surveys in at least 3 countries





## Proportion of European Dermatologists Prescribing Biologics for Psoriasis



Source: European Dermatology Healthcare Survey 2012

Figure 62. Proportion of dermatologists prescribing biologics for psoriasis

# IPC- Dr. Wameru ( Right to the best th)



## CURRENT - 2023

There has been great progress in research with treatment options such as Topicals, Biologics, biosimilars, etc

but

**Inequalities** and limited **access** in many regions

**High cost** of medications and limited insurance coverage in middle and low- income countries

## Optimal treatment and holistic care



Expanding measurement beyond clinical endpoints



Incorporating patient-reported outcomes in study designs



Evaluating overall improvement by using quality of life and mental health tools – DLQI

# POSTERS- Miembros AEDV



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>–8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Comorbidity patterns in patients with psoriasis using network analysis in Aragon

**Manuel Almenara-Blasco**<sup>(1)</sup> - **Jonás Carmona-Pirez**<sup>(2)</sup> - **Tamara Gracia-Cazaña**<sup>(1)</sup> - **Beatriz Poblador-Plou**<sup>(2)</sup> - **Juan Blas Perez-Gilaberte**<sup>(3)</sup> - **Alba Navarro-Bielsa**<sup>(1)</sup> - **Antonio Gimeno-Miguel**<sup>(2)</sup> - **Alexandra Prados-Torres**<sup>(2)</sup> - **Yolanda Gilaberte**<sup>(1)</sup>

H.u. Miguel Servet, Dermatology, Zaragoza, Spain<sup>(1)</sup> - Aragon Health Sciences Institute (iacs), IIS Aragón, Epichron Research Group, Zaragoza, Spain<sup>(2)</sup> - H.u. Miguel Servet, Internal Medicine, Zaragoza, Spain<sup>(3)</sup>

# POSTERS- Miembros AEDV



Psoriasis

## Comorbidity patterns in using network analysis

**Manuel Almenara-Blasco**<sup>(1)</sup> - **Jonás Carm**  
**Beatriz Poblador-Plou**<sup>(2)</sup> - **Juan Blas Per**  
**Antonio Gimeno-Miguel**<sup>(2)</sup> - **Alexandra P**

H.u. Miguel Servet, Dermatology, Zaragoza, Spain  
Epichron Research Group, Zaragoza, Spain<sup>(2)</sup> - H.u.

### MATERIALS AND METHOD:

We conducted a retrospective observational study in the EpiChron Cohort, which links socio-demographic and clinical data from all the users of the public health system of the Spanish region of Aragón (1.3M people). The population included all psoriatic patients from 2010 to 2019 and was stratified by sex and into five age groups (0-11, 12-17, 18-44, 45-64, and  $\geq 65$  years). We performed a descriptive analysis of the demographic characteristics. Then, a network analysis was done to analyze the association between comorbidities based on the tetrachoric correlations (statistical significance at a p-value of 0.01).

### RESULTS:

We obtained a cohort of 32.197 patients with psoriasis (54% men). The most frequently found comorbidities were respiratory, cardio-metabolic, and mental health disorders. Comorbidities were combined into 21 disease patterns. The cardio-metabolic pattern was the most consistently described in all stratum. This pattern included dyslipidemia and other nutritional/endocrine/metabolic disorders, and the correlation strength between them was among the highest in all groups.

### CONCLUSIONS:

Our study revealed the presence of different clinically meaningful comorbidity patterns in patients with psoriasis. Our results can help to identify which comorbidities deserve special attention and to better understand the physio-pathological mechanisms underlying the disease associations identified.

# POSTERS- Miembros AEDV



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Effectiveness in real world practice after fifty-two weeks of Risankizumab treatment for patients with moderate-to-severe psoriasis: thirty-four patient cohort

**Maria Dolores Benedicto Maldonado <sup>(1)</sup> - Pedro Jose Navarro Guillamon <sup>(1)</sup> - Sara Merino Molina <sup>(1)</sup> - Jorge Alonso Suarez Perez <sup>(1)</sup> - Enrique Herrera Acosta <sup>(1)</sup>**

Hospital Universitario Virgen De La Victoria, Dermatology, Malaga, Spain <sup>(1)</sup>

### OBJECTIVE:

Study the effectiveness and safety after fifty-two weeks of treatment with Risankizumab in patients with moderate-to-severe psoriasis in real world practice.



# POSTERS- Miembros AEDV

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

Eff  
we  
wit  
pat

Maria  
Meri

Hospit

OBJEC  
Study  
patier



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Certolizumab for the treatment of psoriasis: experience in our department

Luca Schneller-Pavelescu <sup>(1)</sup> - Pedro Álvarez-Chinchilla <sup>(1)</sup> - Eduardo Vergara-de  
Caso <sup>(1)</sup> - Luis Miguel Gallego-Torrone <sup>(1)</sup> - José Vicente-García <sup>(1)</sup>

Hospital Vega Baja, Dermatology, Orihuela, Spain <sup>(1)</sup>

# POSTERS- Miembros AEDV



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

Eff  
we  
wit  
pat

Maria  
Meri

Hospit

OBJEC  
Study  
patier



Psoriasis

## Certolizumab for the treatment experience in our department

Luca Schneller-Pavelescu <sup>(1)</sup> - Pedro Álvarez Caso <sup>(1)</sup> - Luis Miguel Gallego-Torrone <sup>(1)</sup> - Jo

Hospital Vega Baja, Dermatology, Orihuela, Spain <sup>(1)</sup>



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Guselkumab dosing interval optimization in adult patients with moderate-to-severe Psoriasis switching from ustekinumab

Ricardo Ruiz Villaverde <sup>(1)</sup> - Fiorella Vasquez-Chinchay <sup>(2)</sup> - Lourdes Rodriguez Fernandez-Freire <sup>(3)</sup> - Jose Carlos Armario-Hita <sup>(4)</sup> - Amalia Perez-Gil <sup>(5)</sup> - Manuel Galan-Gutierrez <sup>(6)</sup>

Hospital Universitario San Cecilio, Dermatology, Granada, Spain <sup>(1)</sup> - Hospital Quiron Salud, Dermatology, Sevilla, Spain <sup>(2)</sup> - Hospital Virgen Del Rocio, Dermatology, Sevilla, Spain <sup>(3)</sup> - Hospital Universitario De Puerto Real, Dermatology, Puerto Real, Spain <sup>(4)</sup> - Hospital De Valme, Dermatology, Sevilla, Spain <sup>(5)</sup> - Hospital Universitario Reina Sofía, Dermatology, Córdoba, Spain <sup>(6)</sup>

# POSTERS- Miembros AEDV



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE



Psoriasis

Eff  
we  
wit  
pat  
Mari  
Meri

Hospit

OBJEC  
Study  
patier



Psoriasis

## Certolizumab for the treatment experience in our department

Luca Schneller-Pavelescu<sup>(1)</sup> - Pedro Álvarez Caso<sup>(1)</sup> - Luis Miguel Gallego-Torrone<sup>(1)</sup> - Jo

Hospital Vega Baja, Dermatology, Orihuela, Spain<sup>(1)</sup>

Psoriasis

## Guselkumab efficacy and safety for moderate-to-severe psoriasis: Real-world experience

Gustavo Guillermo Garriga-Martina<sup>(1)</sup> - Jorge Alonso Suárez-Pérez<sup>(1)</sup> - Enrique Herrera-Acosta<sup>(1)</sup>

Hospital Universitario Virgen De La Victoria, Dermatology Department, Málaga, Spain<sup>(1)</sup>



3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Guselkumab dosing interval optimization in adult patients with moderate-to-severe Psoriasis switching from ustekinumab

Ricardo Ruiz Villaverde<sup>(1)</sup> - Fiorella Vasquez-Chinchay<sup>(2)</sup> - Lourdes Rodriguez Fernandez-Freire<sup>(3)</sup> - Jose Carlos Armario-Hita<sup>(4)</sup> - Amalia Perez-Gil<sup>(5)</sup> - Manuel Galan-Gutierrez<sup>(6)</sup>

Hospital Universitario San Cecilio, Dermatology, Granada, Spain<sup>(1)</sup> - Hospital Quiron Salud, Dermatology, Sevilla, Spain<sup>(2)</sup> - Hospital Virgen Del Rocio, Dermatology, Sevilla, Spain<sup>(3)</sup> - Hospital Universitario De Puerto Real, Dermatology, Puerto Real, Spain<sup>(4)</sup> - Hospital De Valme, Dermatology, Sevilla, Spain<sup>(5)</sup> - Hospital Universitario Reina Sofía, Dermatology, Córdoba, Spain<sup>(6)</sup>



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## First case series of bimekizumab for psoriasis treatment in real-world setting

**Maria Aranzazu Torrijos Aguilar<sup>(1)</sup> - Pablo Hernández Bel<sup>(2)</sup> - Rafael Carmena Ramón<sup>(1)</sup> - Manel Velasco Pastor<sup>(1)</sup>**

Arnau Vilanova Lliria, Dermatology, Valencia, Spain<sup>(1)</sup> - General Hospital Valencia, Valencia, Spain<sup>(2)</sup>

---



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
7<sup>th</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## First case series of treatment in real-w

**Maria Aranzazu Torrijos Aguilar** (1) - **Ramón** (1) - **Manel Velasco Pastor**

Arnau Vilanova Lliria, Dermatology, Valer



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Real-Life Effectiveness and Safety of Risankizumab in 74 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study

**Lourdes Rodriguez Fernandez-Freire** (1) - **Ricardo Ruiz-Villaverde** (2) - **Juan Marquez-Enriquez** (3) - **Amalia Perez-Gil** (4) - **Leandro Martinez-Pilar** (5) - **Manuel Galan-Gutierrez** (6)

Hospital Universitario Virgen Del Rocio, Dermatología, Sevilla, Spain (1) - Hospital U. san Cecilio, Dermatología, Granada, Spain (2) - Hospital U. Jerez, Dermatología, Jerez De La Frontera, Spain (3) - Hospital U. Nuestra Señora De Valme, Dermatología, Sevilla, Spain (4) - Hospital U. Carlos Haya, Dermatología, Malaga, Spain (5) - Hospital U. Reina Sofia, Dermatología, Cordoba, Spain (6)



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>–8<sup>th</sup> JULY 2023, SINGAPORE



Psoriasis

## Superresponders in moderate-severe psoriasis under Guselkumab treatment: Myths, realities and future perspectives

**Ricardo Ruiz Villaverde<sup>(1)</sup> - Fiorella Vasquez-Chinchay<sup>(2)</sup> - Lourdees Rodriguez Fernandez-Freire<sup>(3)</sup> - Jose Carlos Armario-Hita<sup>(4)</sup> - Amalia Perez-Gil<sup>(5)</sup> - Manuel Galán-Gutierrez<sup>(6)</sup>**

Hospital Universitario San Cecilio, Dermatology, Granada, Spain<sup>(1)</sup> - Hospital Quiron Salud, Dermatology, Sevilla, Spain<sup>(2)</sup> - Hospital Virgen Del Rocio, Dermatology, Sevilla, Spain<sup>(3)</sup> - Hospital Universitario De Puerto Real, Dermatology, Puerto Real, Spain<sup>(4)</sup> - Hospital De Valme, Dermatology, Sevilla, Spain<sup>(5)</sup> - Hospital Universitario Reina Sofía, Dermatology, Córdoba, Spain<sup>(6)</sup>



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Superresponders under Guselki and future pe

Ricardo Ruiz Villaverde  
Fernandez-Freire <sup>(3)</sup> - Jo  
Gutierrez <sup>(6)</sup>

Hospital Universitario San Ce  
Sevilla, Spain <sup>(2)</sup> - Hospital Vir  
Puerto Real, Dermatology, Pu  
Hospital Universitario Reina S



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Switch to adalimumab biosimilar in psoriatic patients under well control with bioriginal

Miriam Fernandez-Parrado <sup>(1)</sup> - Ingrid Hiltun <sup>(1)</sup> - Gerald Selda <sup>(2)</sup> - Monica Larrea-Garcia <sup>(1)</sup> - Josune Mitxelena <sup>(1)</sup> - Juan Ignacio Yanguas-Bayona <sup>(1)</sup>

Hospital Universitario De Navarra, Dermatology, Pamplona, Spain <sup>(1)</sup> - Hospital Universitario Ramón Y Cajal, Dermatology, Madrid, Spain <sup>(2)</sup>



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Superresponders under Guselkumab and future perspectives

Ricardo Ruiz Villaverde  
Fernandez-Freire <sup>(3)</sup> - Jo  
Gutierrez <sup>(6)</sup>

Hospital Universitario San Ce  
Sevilla, Spain <sup>(2)</sup> - Hospital Vir  
Puerto Real, Dermatology, Pu  
Hospital Universitario Reina S



Psori

**Sv  
pa**

Miri  
Gar

Hosp  
Caja



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

Psoriasis

## Tildrakizumab: Efficacy and safety in mid-term ( 52 weeks ) on real clinical practice in 32 patients with moderate-to-severe psoriasis

Lourdes Rodriguez Fernandez-Freire <sup>(1)</sup> - Juan Ortiz <sup>(1)</sup> - Juan Carlos Hernandez <sup>(1)</sup> - Mercedes Morillo <sup>(1)</sup> - Roman Barabash <sup>(1)</sup> - Julian Conejo-Mir <sup>(1)</sup>

Hospital Universitario Virgen Del Rocio, Dermatology, Sevilla, Spain <sup>(1)</sup>



# POSTERS Psoriasis novedades



**Abstract Book**  
ABSTRACT DRIVEN



25<sup>th</sup> World Congress  
of Dermatology  
SINGAPORE 2023

DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>–8<sup>th</sup> JULY 2023, SINGAPORE

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023

Psoriasis

## **Efficacy and safety of roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial**

**Melinda Gooderham<sup>(1)</sup> - Jerry Bagel<sup>(2)</sup> - Janet Dubois<sup>(3)</sup> - Leon Kircik<sup>(4)</sup> - Benjamin Lockshin<sup>(5)</sup> - Kim Papp<sup>(6)</sup> - Jennifer Soung<sup>(7)</sup> - David Krupa<sup>(8)</sup> - Patrick Burnett<sup>(8)</sup> - David Berk<sup>(8)</sup> - David Chu<sup>(8)</sup>**

Skin Centre For Dermatology, Probity Medical Research And Queen's University, Peterborough, Canada<sup>(1)</sup>  
- Psoriasis Treatment Center Of Central New Jersey, East Windsor, United States Of America<sup>(2)</sup> -  
Dermresearch, Inc., Austin, United States Of America<sup>(3)</sup> - Icahn School Of Medicine At Mount Sinai, New  
York, United States Of America<sup>(4)</sup> - Dermassociates, Llc, Rockville, United States Of America<sup>(5)</sup> - Probity  
Medical Research And Alliance Clinical Research, Waterloo, United States Of America<sup>(6)</sup> - Southern  
California Dermatology, Santa Ana, United States Of America<sup>(7)</sup> - Arcutis Biotherapeutics, Inc., Westlake  
Village, United States Of America<sup>(8)</sup>

# POSTERS Psoriasis novedades



**Abstract Book**  
ABSTRACT DRIVEN



25<sup>th</sup> World Congress  
of Dermatology  
SINGAPORE 2023

DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>–8<sup>th</sup> JULY 2023, SINGAPORE

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023

Psoriasis

## Efficacy and safety of roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial

Me  
Loc  
Dat  
Skir  
- Psi  
Deri  
York  
Med  
Cali  
Villa

RESULTS:

Significantly more roflumilast-treated than vehicle-treated patients achieved S-IGA Success (66.4% vs 27.8%;  $P < 0.0001$ ) and B-IGA Success (45.5% vs. 20.1%;  $P < 0.0001$ ) with 40.0% and 27.8% of roflumilast-treated patients achieving S-IGA and B-IGA of Clear, respectively ( $P < 0.0001$ ; nominal for B-IGA) at Week 8. All secondary endpoints achieved statistical significance. Notably, improvement in itch was observed as early as 24 hours following first application ( $P = 0.0164$ ) as measured by change from baseline in Scalp Itch-Numeric Rating Score. Safety and local tolerability were favorable with  $\geq 95\%$  of patients reporting no or mild sensation. Rates of discontinuation due to adverse events were low and similar among roflumilast-treated (1.8%) and vehicle-treated (1.3%) patients.

# POSTERS Psoriasis novedades



**Abstract Book**  
ABSTRACT DRIVEN



25<sup>th</sup> World Congress  
of Dermatology  
SINGAPORE 2023

DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>–8<sup>th</sup> JULY 2023, SINGAPORE

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023

Psoriasis

## Efficacy and safety of roflumilast foam 0.3% in

### CONCLUSIONS:

Roflumilast foam 0.3% improved scalp and body psoriasis across multiple efficacy endpoints while demonstrating favorable safety and tolerability. Sponsored by Arcutis Biotherapeutics, Inc.

Deri  
York  
Med  
Cali  
Villa

( $P < 0.0001$ ; nominal for B-IGA) at Week 8. All secondary endpoints achieved statistical significance. Notably, improvement in itch was observed as early as 24 hours following first application ( $P = 0.0164$ ) as measured by change from baseline in Scalp Itch-Numeric Rating Score. Safety and local tolerability were favorable with  $\geq 95\%$  of patients reporting no or mild sensation. Rates of discontinuation due to adverse events were low and similar among roflumilast-treated (1.8%) and vehicle-treated (1.3%) patients.



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup>-8<sup>th</sup> JULY 2023, SINGAPORE

**Session code:** LB01 | **Session title:** "Late-breaker 1" | **Day:** Tuesday, 4<sup>th</sup> July | **Time:** 14:30-15:50 |  
**Room:** Level 3 - Room 330

**LB** Late-Breaker

Psoriasis

## A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER 1

**R Bissonnette**<sup>(1)</sup> - **A Pinter**<sup>(2)</sup> - **L Ferris**<sup>(3)</sup> - **S Gerdes**<sup>(4)</sup> - **P Rich**<sup>(5)</sup> - **M Miller**<sup>(6)</sup> - **Y-K Shen**<sup>(7)</sup> - **C Deklotz**<sup>(6)</sup> - **Ka Papp**<sup>(8)</sup>

Innovaderm Research, Dermatology, Montreal, Canada<sup>(1)</sup> - Goethe University Frankfurt, Dermatology, Venereology And Allergology, Frankfurt, Germany<sup>(2)</sup> - University Of Pittsburgh, Dermatology, Pittsburgh, United States Of America<sup>(3)</sup> - University Medical Center Schleswig-holstein Campus Kiel, Center For Inflammatory Skin Diseases, Kiel, Germany<sup>(4)</sup> - Oregon Dermatology And Research Center, Dermatology, Portland, United States Of America<sup>(5)</sup> - Janssen Research & Development, Llc, Immunology, Spring House, United States Of America<sup>(6)</sup> - Janssen Research & Development, Llc, Biostatistics, Spring House, United States Of America<sup>(7)</sup> - Alliance Clinical Trials And Probity Medical Research; Adjunct Professor Of Medicine, University Of Toronto, Dermatology, Waterloo, Canada<sup>(8)</sup>

HIGHLIGHTS



SINGAPORE

3-8 / july / 2023



Session code: LBO  
Room: Level 3 - Ro

Psoriasis

## A Phase ranging Treatment Psoriasis

R Bissonnett  
Shen<sup>(7)</sup> - C D

Innovaderm Re  
Venereology An  
United States O  
Inflammatory SI  
Portland, Unite  
United States O  
States Of Ameri  
University Of Tc

### RESULTS:

At W16, the proportions of patients achieving PASI75 were PBO 9.3%, JNJ-77242113: 25mg QD 37.2%, 50mg QD 58.1%, 25mg BID 51.2%, 100mg QD 65.1%, 100mg BID 78.6%, demonstrating significant dose response. PASI90 response rates were PBO 2.3%, JNJ-77242113: 25mg QD 25.6%, 50mg QD 51.2%, 25mg BID 26.8%, 100mg QD 46.5%, 100mg BID 59.5%. PASI75 and PASI90 response rates for all JNJ-77242113 doses were significantly higher than



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

PBO (nominal  $p \leq 0.002$  for all comparisons). The proportions of patients with adverse events (AEs) were comparable between JNJ-77242113 groups and the PBO group. Most frequently reported AEs were COVID-19 and nasopharyngitis with no dose-dependent trends.



Session code: LBO  
Room: Level 3 - Ro

Psoriasis

## A Phase ranging Treatment Psoriasis

R Bissonnett  
Shen<sup>(7)</sup> - C D

Innovaderm Re  
Venereology An  
United States O  
Inflammatory SI  
Portland, Unitec  
United States O  
States Of Ameri  
University Of Tc

### RESULTS:

At W16, the proportions of patients achieving PASI75 were PBO 9.3%, JNJ-77242113: 25mg QD 37.2%, 50mg QD 58.1%, 25mg BID 51.2%, 100mg QD 65.1%, 100mg BID 78.6%, demonstrating significant dose response. PASI90 response rates were PBO 2.3%, JNJ-77242113: 25mg QD 25.6%

PASI75 and PAS

### CONCLUSIONS:

JNJ-77242113 is a first-in-class oral IL-23R peptide antagonist that demonstrated significantly greater efficacy compared with PBO in patients with moderate-to-severe plaque psoriasis and was well-tolerated in all treatment groups.



DERMATOLOGY BEYOND BORDERS  
SCIENCE · CARE · COMMUNITIES  
3<sup>rd</sup> - 8<sup>th</sup> JULY 2023, SINGAPORE

PBO (nominal  $p \leq 0.002$  for all comparisons). The proportions of patients with adverse events (AEs) were comparable between JNJ-77242113 groups and the PBO group. Most frequently reported AEs were COVID-19 and nasopharyngitis with no dose-dependent trends.







**HIGHLIGHTS**



**SINGAPORE**

3-8 / july / 2023

Con el patrocinio de:



Iniciativa científica de:



ACADEMIA ESPAÑOLA  
DE DERMATOLOGÍA  
Y VENEREOLÓGIA